Global Tuberculosis Drugs Market, By Therapy Type (First Line Drugs Therapy, Second Line Drugs Therapy, Combination Drugs Therapy), and Geography - Insights, Opportunity Analysis, and Industry Forecast till 2024

Tuberculosis Drugs: Hopes Pinned on Renewed Government Investments in Emerging Economies

Tuberculosis is a chronic condition that is often undermined, though it can be fatal if left unchecked. Thankfully, extensive awareness campaigns and initiatives by various governments to curb the menace is bearing fruit. Tuberculosis treatment helped prevent 49 million fatalities associated with the condition between 2000 and 2015. However, there are still some prominent diagnostic and treatment slits that continue. In 2015, approximately 6.1 million newly diagnosed tuberculosis cases were reported by national authorities of various countries and reported to World Health Organization. This high increase in tuberculosis cases during 2013–2015, was typically due to a 34% increase in tuberculosis cases notifications in India. Globally, there was 4.3 million new tuberculosis cases gap between incident and reported cases, out of which India, Indonesia, and Nigeria comprises almost half of these newly diagnosed cases impacting high revenue generation in tuberculosis drugs market.

In 2015, out of 580 thousand people who were eligible for multidrug resistance tuberculosis treatment, only 125 000 (20%) were registered. Five countries, namely India, China, the Russian Federation, Indonesia, and Nigeria account for over 60% of this gap.  Worldwide, the multidrug resistance tuberculosis treatment success rate was 50-52% in 2013 and in 2015, approximately 55% of reported new tuberculosis patients had a documented HIV test result. The HIV-positive tuberculosis patients on an antiretroviral therapy was around 78%. This led to the wider understanding about the ailment and government and non-governmental organizations alike are focusing on developing tuberculosis preventive treatment and increasing their access to the general populace. Thus, it would boost the tuberculosis drugs market over the forecast period.

The global tuberculosis drugs market was valued at US$ 1,333.1 million in 2015 and is expected to witness a CAGR of 23.4% during the forecast period (2016 – 2024).

Figure 1. Global Tuberculosis Drugs Market Share, By Therapy Type (%)

Tuberculosis Drugs Market

Source: Coherent Market Insights Analysis (2017)

With the significant increase in revenue of tuberculosis drugs market, over last decade, more than 10 chemical moiety have advanced into the clinical trial development pipeline, which include six new chemical moiety significantly and specifically developed for tuberculosis. Though there are molecules in clinical development phase, the global drug pipeline for tuberculosis is still not sufficient to address the unmet needs of treatment. Many pharmaceutical companies have produced molecules that are under clinical trials and the key challenges by any company to develop new product to treat tuberculosis and effects the tuberculosis drugs market are the needs for drugs in combination therapy, new trial strategies, studies on pediatric TB drugs, population and increased clinical trial capacity and clear regulatory guidelines.

High funding for research and development and clinical trials drugs to boost the tuberculosis drugs market

There was around US$ 6.6 billion revenue accessible for tuberculosis care and prevention in many of the low and middle-income countries in 2016, out of which 84% was from domestic sources. However, national tuberculosis program (NTPs) in low income countries linger to depend on international donors or foreign healthcare agencies to fund them approximately 90%. Investments in low income countries and middle income countries declined by US$ 2 billion to US$ 8.3 billion, which was needed in 2016. There were many enhancements needed in overall healthcare financing to curb new tuberculosis cases proportionally boosting tuberculosis drugs market. Government expenditures on healthcare in specific to tuberculosis in 2014 were less than the World Health Organization set a benchmark of at least 6% of gross domestic product in around 150 countries. Private expenditures surpassed 45% of total healthcare expenditures in tuberculosis in 46 countries, which also includes 11 of the 30 high tuberculosis burden countries. Presently, there are around 13 vaccine candidates in clinical development, which include trial drugs for prevention of tuberculosis infection and trial drugs for prevention of tuberculosis disease in people with Latent Tuberculosis Disease. According to WHO, at least US$ 2 billion investment is needed every year for tuberculosis research and development. In stark contrast, capital investment during 2005–2014 was reported to be US$ 0.7 billion annually. Infusion of investments in research and development would significantly improve the tuberculosis drugs market outlook.

Tuberculosis is a deadly infectious disease that affects the lungs. Among diseases, tuberculosis is the second largest cause of death worldwide. Tuberculosis are broadly classified as latent tuberculosis and active tuberculosis. Globally around 10% of latent infections develop into active tuberculosis. Infections that do not show any symptoms are called latent tuberculosis. In 2015, the malady resulted in 1.8 million deaths and 10.4 million new reported cases. In 2015, in the U.S., there were 9,557 tuberculosis cases reported. Based on the statistics of Center for Disease Control and Prevention, a 1.6% increase in the number of tuberculosis cases was observed in 2015 as compared to those reported in 2014.  Though there is an increase in the number of tuberculosis cases, the incidence rate per 100,000 persons has been around 3.0 since 2013.

Market Dynamics

Asia and Africa are the largest markets for tuberculosis drugs, as these regions have the highest prevalence of TB.  There are many initiatives taken to control the TB increasing cases. The United Nations’ Millennium Development Goals have framed various strategies to reduce TB prevalence and death rates by 2015, which can be achieved by WHO’s Stop TB Strategy. According World Health Organization, in 2006, 61% out of 2.5 million new smear positive cases with DOTS, and are all the new smear cases on the year, and the treatment was successful in 85% cases. The estimated global incidence rate of tuberculosis shown decline rate by 0.6% in 2005 and 2006. In 2006, the incidence rate of tuberculosis became stable in the Europe and is declining gradually in the other WHO countries. World Health Organization has an approximation that the occurrence of tuberculosis and death rates are declining faster than the incidence rate.

Market Taxonomy

This report segments the global tuberculosis drugs market on the basis of therapy type and geography. On the basis of therapy type, the market is categorized into first line drugs, Second line drugs and combination drug therapy. Under First line drugs, the market is further segmented into drugs such as Isoninazid, Rifampicin, Ethambutol, Pryazinamide, and Strepromycin. The second line drugs are further segmented into Injectable, Fluoroquinolones, and Bacteriostatic Agents and Others. For comprehensive understanding of market dynamics, the global tuberculosis drugs market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key features of the study:

  • This report provides in-depth analysis of the tuberculosis drugs market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global tuberculosis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
  • The global tuberculosis drugs market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers for tuberculosis drugs, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the tuberculosis drugs market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Tuberculosis Drugs Market, By Therapy Type:
    • First Line Drugs Therapy
    • Second Line Drugs Therapy
    • Combination Drugs Therapy
  • Global Healthcare Biometrics Market, By Geography:
    • North America
      • U.S.
        • U.S. Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Canada
        • Canada Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
    • Europe
      • U.K.
        • U.K. Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Germany
        • Germany Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Italy
        • Italy Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • France
        • France Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Spain
        • Spain Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Russia
        • Russia Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Rest of Europe
        • Rest of Europe Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
    • Asia-Pacific
      • China
        • China Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • India
        • India Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Japan
        • Japan Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • ASEAN
        • ASEAN Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Australia
        • Australia Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • South Korea
        • South Korea Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Rest of Asia Pacific
        • Rest of Asia Pacific Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
    • Latin America
      • Brazil
        • Brazil Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Mexico
        • Mexico Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Rest of Latin America
        • Rest of Latin America Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
    • Middle East
      • GCC
        • GCC Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Israel
        • Israel Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Rest of Middle East
        • Rest of Middle East Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
    • Africa
      • North Africa
        • North Africa Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • Central Africa
        • Central Africa Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
      • South Africa
        • South Africa Tuberculosis Drug Market, By Therapy Type:
          • First Line Drugs Therapy
          • Second Line Drugs Therapy
          • Combination Drugs Therapy
  • Company Profiles
    • Pfizer Inc *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Lupin Laboratories Ltd
    • AstraZeneca Plc
    • Cadila Pharmaceuticals
    • Novartis AG
    • Alkem Laboratories Ltd
    • Cipla Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Therapy Type
      • Market Snippet By Geography
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Pricing Scenario
    • PEST Analysis
    • Campaigns and Programs
    • Distribution Channel
    • Pipeline Drugs
    • Prevalence and Incidence
  4. Global Tuberculosis Drugs Market, By Therapy Type, 2014 - 2024 (US$ Million)
    • Introduction
      • Market Share Analysis, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, 2014 - 2024
      • Segment Trends
    • First Line Drugs Therapy
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
      • Segment Trend
        • Isoniazid
        • Rifampicin
        • Ethambutol
        • Pyrazinamide
        • Streptomycin
    • Second Line Drugs Therapy
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
      • Segment Trend
        • Injections
        • Fluoroquinolones
        • Bacteriostatic Agents
        • Others
    • Combination Drug Therapy
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
  5. Global Tuberculosis Drugs Market, By Geography, 2014 - 2024 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, For Regions, 2014 – 2024
    • North America
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, By Country, 2014 - 2024
        • U.S.
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Canada
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
    • Europe
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, By Country, 2014 - 2024
        • U.K.
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Germany
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Italy
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • France
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Spain
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Russia
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Rest of Europe
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
    • Asia Pacific
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, By Country, 2014 - 2024
        • China
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • India
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Japan
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • ASEAN
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Australia
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • South Korea
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Rest of Asia Pacific
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
    • Latin America
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, By Country, 2014 - 2024
        • Brazil
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Mexico
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Argentina
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Rest of Latin America
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
    • Middle East
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, By Country, 2014 - 2024
        • GCC Countries
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Israel
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Rest of Middle East
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
    • Africa
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, By Country, 2014 - 2024
        • Northern Africa
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • Central Africa
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
        • South Africa
          • Country Trends
          • Market Size and Forecast, By Therapy Type, 2014 - 2024 (US$ Million)
  6. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Pfizer, Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Lupin Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Astrazeneca plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cadila Pharmaceuticals Ltd.  
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Alkem Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cipla Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 44 figures on "Tuberculosis Drugs - Global forecast to 2024”.         

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

sales@coherentmarketinsights.com

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.